Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.40
FURX's Cash to Debt is ranked higher than
52% of the 1002 Companies
in the Global Business Services industry.

( Industry Median: 1.28 vs. FURX: 0.40 )
FURX' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 0.4

Equity to Asset 0.13
FURX's Equity to Asset is ranked lower than
60% of the 986 Companies
in the Global Business Services industry.

( Industry Median: 0.47 vs. FURX: 0.13 )
FURX' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.96
Current: 0.13

0.13
0.96
F-Score: 2
Z-Score: 5.57
M-Score: -3.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -120.54
FURX's Operating margin (%) is ranked lower than
64% of the 1002 Companies
in the Global Business Services industry.

( Industry Median: 6.96 vs. FURX: -120.54 )
FURX' s 10-Year Operating margin (%) Range
Min: -1081.43   Max: -34.42
Current: -120.54

-1081.43
-34.42
Net-margin (%) -135.68
FURX's Net-margin (%) is ranked lower than
64% of the 1002 Companies
in the Global Business Services industry.

( Industry Median: 4.69 vs. FURX: -135.68 )
FURX' s 10-Year Net-margin (%) Range
Min: -1090.89   Max: -41.79
Current: -135.68

-1090.89
-41.79
ROE (%) -482.97
FURX's ROE (%) is ranked lower than
65% of the 972 Companies
in the Global Business Services industry.

( Industry Median: 10.02 vs. FURX: -482.97 )
FURX' s 10-Year ROE (%) Range
Min: -160.91   Max: -18.13
Current: -482.97

-160.91
-18.13
ROA (%) -64.51
FURX's ROA (%) is ranked lower than
64% of the 1016 Companies
in the Global Business Services industry.

( Industry Median: 4.27 vs. FURX: -64.51 )
FURX' s 10-Year ROA (%) Range
Min: -51.49   Max: -15.98
Current: -64.51

-51.49
-15.98
ROC (Joel Greenblatt) (%) -58129.11
FURX's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 1012 Companies
in the Global Business Services industry.

( Industry Median: 31.39 vs. FURX: -58129.11 )
FURX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -34189.83   Max: -26340.96
Current: -58129.11

-34189.83
-26340.96
» FURX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

FURX Guru Trades in Q3 2013

Chuck Royce 232,865 sh (+245.58%)
Jim Simons Sold Out
» More
Q4 2013

FURX Guru Trades in Q4 2013

Chuck Royce 403,565 sh (+73.3%)
» More
Q1 2014

FURX Guru Trades in Q1 2014

Steven Cohen 83,700 sh (New)
Chuck Royce 355,065 sh (-12.02%)
» More
Q2 2014

FURX Guru Trades in Q2 2014

Jim Simons 27,600 sh (New)
Mario Gabelli 54,400 sh (New)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FURX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-06-30 New Buy0.03%$75.24 - $105.3 $ 104.777%54400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 103.73
FURX's P/B is ranked lower than
56% of the 1098 Companies
in the Global Business Services industry.

( Industry Median: 3.07 vs. FURX: 103.73 )
FURX' s 10-Year P/B Range
Min: 0.64   Max: 104.21
Current: 103.73

0.64
104.21
P/S 28.09
FURX's P/S is ranked lower than
58% of the 1098 Companies
in the Global Business Services industry.

( Industry Median: 1.54 vs. FURX: 28.09 )
FURX' s 10-Year P/S Range
Min: 4.39   Max: 99.79
Current: 28.09

4.39
99.79
EV-to-EBIT -25.73
FURX's EV-to-EBIT is ranked lower than
57% of the 1098 Companies
in the Global Business Services industry.

( Industry Median: 19.32 vs. FURX: -25.73 )
FURX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -25.73

Current Ratio 1.10
FURX's Current Ratio is ranked lower than
52% of the 642 Companies
in the Global Business Services industry.

( Industry Median: 1.52 vs. FURX: 1.10 )
FURX' s 10-Year Current Ratio Range
Min: 0.92   Max: 17.23
Current: 1.1

0.92
17.23
Quick Ratio 1.10
FURX's Quick Ratio is ranked higher than
54% of the 642 Companies
in the Global Business Services industry.

( Industry Median: 1.38 vs. FURX: 1.10 )
FURX' s 10-Year Quick Ratio Range
Min: 0.92   Max: 17.23
Current: 1.1

0.92
17.23

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.25
FURX's Price/Median PS Value is ranked lower than
51% of the 1098 Companies
in the Global Business Services industry.

( Industry Median: 1.16 vs. FURX: 2.25 )
FURX' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 7.51
Current: 2.25

0.38
7.51

Business Description

Industry: Business Services » Business Services
Compare: » details
Traded in other countries:FUF.Germany
Furiex Pharmaceuticals, Inc. is a Delaware Corporation. The Company is a drug development collaboration company that uses clinical development strategies to increase the value of partnered pharmaceutical assets and accelerate their development timelines. Its strategy is to invest in drug candidates that have a relatively straightforward path to regulatory approval and a large addressable market. Every drug candidate it reviews is subjected to its rigorous due diligence process by its team of experts who possess experience in all aspects of the drug development process. Currently, it has rights to several compounds in various stages of development and commercialization, including: Rights to royalties and regulatory and sales-based milestone payments from Takeda Pharmaceuticals Company Limited, for alogliptin and SYR-472. Takeda received regulatory and pricing approval in Japan during the second quarter of 2010 for alogliptin for the treatment of Type-2 diabetes. Takeda markets alogliptin in Japan under the name Nesina. Rights to royalties and regulatory and sales-based milestones from the collaboration with Alza Corporation, an affiliate of Janssen Pharmaceutica, N.V., for Priligy, the first approved treatment in the world for premature ejaculation. Priligy is currently marketed in 15 countries in Europe, Asia-Pacific and Latin America. A compound licensed from Janssen, (an affiliate of Johnson & Johnson), in November 2009 that is a mu opioid receptor agonist and delta opioid receptor antagonist, which it call MuDelta, for the treatment of diarrhea-predominant irritable bowel syndrome. It completed a Phase II Proof-of-Concept clinical trial during 2011 which demonstrated that MuDelta has a favorable efficacy and safety profile. It has two Phase III-ready products in clinical development, with exclusive license rights to both products: MuDelta and JNJ-Q2. In addition it have one compound in Phase III development with a collaborator, SYR-472, and two compounds that are commercialized by collaborators, for which it are eligible to receive regulatory milestone payments plus worldwide sales royalty and milestone payments. These compounds, Nesina and Priligy, are currently marketed outside of the United States, and it has no further development obligations for any of these three compounds. A fluoroquinolone antibiotic licensed from Janssen in November 2009, which it calls JNJ-Q2, for the treatment of acute bacterial skin and skin structure infections, such as abscesses that occur deep in the skin layers, and respiratory infections. The manufacturing, testing, labeling, approval and storage of the Company's products are subject to rigorous regulation by numerous governmental authorities in the United States and other countries at the federal, state and local level, including the FDA.
» More Articles for FURX

Headlines

Articles On GuruFocus.com
Look at All these Spinoffs Beating the Market Jul 06 2011 

More From Other Websites
FURIEX PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 03 2014
Salix Pharmaceuticals Surges on Positive IBS Data Jul 02 2014
Actavis Completes Acquisition of Furiex Pharmaceuticals Jul 02 2014
FURIEX PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jul 01 2014
U.S. allows Actavis Plc's purchase of Forest Labs with conditions Jun 30 2014
Insider Trading Alert - FURX, EGP And FLT Traded By Insiders Jun 13 2014
FURIEX PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2014
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection with the Sale of Furiex... May 22 2014
FURIEX PHARMACEUTICALS, INC. Financials May 16 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims... May 13 2014
FURIEX PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 09 2014
FURIEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2014
Furiex Pharmaceuticals Reports First Quarter 2014 Financial Results May 07 2014
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Furiex Pharmaceuticals, Inc. in... May 05 2014
INVESTOR ALERT – FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the... May 02 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Furiex Pharmaceuticals, Inc.... May 01 2014
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale... Apr 30 2014
Why traders are buying Furiex puts Apr 30 2014
Actavis Q1 Earnings Beat On Generic Cymbalta Surprise Apr 30 2014
Actavis Reporting Q1 Earnings Amid Merger Frenzy Apr 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK